2 variant. Novavax recently struck a licensing deal worth at least $1.2 billion with Sanofi for its COVID vaccine, bolstering ...
Recent health news covers various incidents, including a fire at Novo Nordisk’s headquarters, mergers by Gerresheimer and Biogen, avian flu cases in humans, and lawsuits against Johnson & Johnson.
Novavax could receive up to $700 million in development milestone payments from this deal. The biotech will also earn ...
The recent run of good fortune for vaccine maker Novavax (NASDAQ:NVAX continues. Following the major licensing deal with ...
Novavax (NVAX) stock as Shah Capital withdraws its proxy campaign against the company following a licensing agreement with ...
A Novavax shareholder that had been waging a campaign to oust three board members at the Gaithersburg company has now ...
Under a deal signed on May 10, the French drugmaker will take a 4.9% stake in Novavax for $70 million at a lofty valuation.
Novavax ( NVAX -9.65%) has been a highly volatile stock in recent years, and that volatility is on full display again this ...
The past five days have been a rollercoaster for Novavax ... deal with French pharmaceutical giant Sanofi. Sanofi and Novavax have struck a comprehensive agreement to expand access to COVID-19 ...
Under the licensing agreement, Sanofi will pay Novavax $500 million upfront with up to $700 million in milestone payments, making the deal worth up to $1.2 billion. The agreement also gives Sanofi ...
The French drugmaker also has the sole license to develop and market the Novavax vaccine ... million from Sanofi, plus mid-single-digit royalties. In addition to the above deal, Novavax has ...
According to the analyst, this deal also encompasses a licensing agreement for Novavax's adjuvant, a component that enhances the immune response of vaccines. The financial infusion from Sanofi is ...